[Sotalol--atrial fibrillation, reduced renal function and sudden death]
- PMID: 9844513
[Sotalol--atrial fibrillation, reduced renal function and sudden death]
Abstract
Sotalol is a betablocker with additional antiarrythmic properties. Its pharmacokinetic properties may lead to increased serum levels of the drug in patients with reduced kidney function. We report on a case in which kidney failure in a patient using sotalol for paroxysmal atrial fibrillation gave rise to torsade de pointes ventricular tachycardia and, eventually, sudden death. Gradual prolongation of the QT interval suggested an overdose of sotalol. Sotalol has been commonly used in cases of angina pectoris and hypertension. The recently published SWORD study has, however, changed the indications for its use, and sotalol should now only be used in cases of severe supraventricular and ventricular arrythmias.
Similar articles
-
[Sotalol and torsades de pointes ventricular tachycardia].Ugeskr Laeger. 1996 May 6;158(19):2711-6. Ugeskr Laeger. 1996. PMID: 8744073 Danish.
-
Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.Int J Cardiol. 2005 Dec 7;105(3):337-9. doi: 10.1016/j.ijcard.2004.11.031. Epub 2005 Jun 27. Int J Cardiol. 2005. PMID: 15985302
-
Sotalol-induced torsades de pointes in patients with renal failure.Can J Cardiol. 1997 Jan;13(1):55-8. Can J Cardiol. 1997. PMID: 9039065
-
Torsade de pointes with sotalol overdose treated successfully with lidocaine.Can J Cardiol. 1998 May;14(5):753-6. Can J Cardiol. 1998. PMID: 9627533 Review.
-
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.Pharmacotherapy. 2007 Sep;27(9):1297-305. doi: 10.1592/phco.27.9.1297. Pharmacotherapy. 2007. PMID: 17723083 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical